The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia
Open Access
- 17 July 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 4806-4809
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myelomaBlood, 2021
- Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell LeukemiaClinical Lymphoma Myeloma and Leukemia, 2021
- Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myelomaBlood Cancer Journal, 2018
- Secondary plasma cell leukemia: a multicenter retrospective study of 101 patientsLeukemia & Lymphoma, 2018
- Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population‐based data from the Swedish Myeloma RegisterEuropean Journal of Haematology, 2017
- Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definitionHaematologica, 2017
- Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myelomaLeukemia, 2014
- How I treat plasma cell leukemiaBlood, 2012
- Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironmentLeukemia, 2005
- Multiple myeloma: increasing evidence for a multistep transformation process.1998